litlas
Log inCreate account

Ronald M. Bukowski

Active 1981–2016

114
Papers
36,983
Citations
90
h-index
114
i10-index

Citations

Citations per year for Ronald M. Bukowski1956: 2 citations1982: 1 citations1985: 1 citations1986: 1 citations1987: 7 citations1988: 6 citations1989: 3 citations1990: 7 citations1991: 8 citations1992: 15 citations1993: 19 citations1994: 15 citations1995: 27 citations1996: 29 citations1997: 36 citations1998: 32 citations1999: 86 citations2000: 71 citations2001: 82 citations2002: 66 citations2003: 69 citations2004: 110 citations2005: 117 citations2006: 209 citations2007: 351 citations2008: 442 citations2009: 528 citations2010: 567 citations2011: 465 citations2012: 439 citations2013: 387 citations2014: 280 citations2015: 291 citations2016: 231 citations2017: 185 citations2018: 209 citations2019: 638 citations2020: 650 citations2021: 508 citations2022: 336 citations2023: 263 citations2024: 311 citations2025: 104 citations2026: 3 citations1957–1981: no citations, so these years are not shown1983–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,588 citing papers, 30.5% of this breakdownChina: 656 citing papers, 7.7% of this breakdownItaly: 527 citing papers, 6.2% of this breakdownFrance: 515 citing papers, 6.1% of this breakdownUnited Kingdom: 502 citing papers, 5.9% of this breakdownGermany: 396 citing papers, 4.7% of this breakdownJapan: 331 citing papers, 3.9% of this breakdownCanada: 307 citing papers, 3.6% of this breakdownNetherlands: 258 citing papers, 3% of this breakdownSpain: 226 citing papers, 2.6% of this breakdownAustralia: 167 citing papers, 2% of this breakdownBelgium: 156 citing papers, 1.8% of this breakdown
0%30.5%Other 22%

Institutions

Fields

  • Medicine65.6%
  • Biochemistry, Genetics and Molecular Biology19.1%
  • Immunology and Microbiology11%
  • Materials Science0.8%
  • Neuroscience0.7%
  • Chemistry0.5%
  • Other2.3%

Topics

  • Renal cell carcinoma treatment10.7%
  • Cancer Immunotherapy and Biomarkers5.1%
  • Renal and related cancers3.2%
  • Angiogenesis and VEGF in Cancer3.1%
  • Immunotherapy and Immune Responses3.1%
  • Cancer Genomics and Diagnostics2.4%
  • Other72.4%

Coauthors

All papers

Open in search
  1. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Authors: Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark Warren, Ali Golshayan, Chakshu Sahi, Bernhard J. Eigl, Joseph D. Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N., Christian Kollmannsberger, David F. McDermott, William Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri - Journal of Clinical Oncology 2009 cited by 2,130

  2. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin - New England Journal of Medicine 2007 cited by 5,756

  3. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

    Authors: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski - New England Journal of Medicine 2007 cited by 4,784

  4. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin - Journal of Clinical Oncology 2009 cited by 2,189

  5. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

    Authors: James H. Finke, Brian I. Rini, Joanna Ireland, Patricia Rayman, Amy L. Richmond, Ali Golshayan, Laura S. Wood, Paul Elson, J. Luz Tovar García, Robert Dreicer, Ronald M. Bukowski - Clinical Cancer Research 2008 cited by 485

  6. Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Authors: Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert W. Ross, Peter D. Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan - Journal of Clinical Oncology 2012 cited by 458

  7. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

    Authors: Jennifer S. Ko, Arnold H. Zea, Brian I. Rini, Joanna Ireland, Paul Elson, Peter A. Cohen, Ali Golshayan, Patricia Rayman, Laura S. Wood, Jorge A. García, Robert Dreicer, Ronald M. Bukowski, James H. Finke - Clinical Cancer Research 2009 cited by 852

  8. Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim Margolin, Jaime R. Merchan, George Wilding, Michelle S. Ginsberg, Jennifer Bacik, Sindy T. Kim, Charles M. Baum, M. Dror Michaelson - JAMA 2006 cited by 1,228

  9. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Authors: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria Hofilena, Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski - Journal of Clinical Oncology 2009 cited by 1,083

  10. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

    Authors: Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski, Louis Lacombe, Gorelov Ai, S. Gorelov, Peter Mulders, Henryk Zieliński, Axel Hoos, Florentina Teofilovici, Leah Isakov, Robert C. Flanigan, Robert A. Figlin, Renu Gupta, Bernard Escudier - The Lancet 2008 cited by 330

  11. Pazopanib

    Authors: Ronald M. Bukowski, Uma Yasothan, Peter Kirkpatrick - Nature Reviews Drug Discovery 2009 cited by 120

  12. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

    Authors: Robert J. Motzer, Ashok Rakhit, Lawrence H. Schwartz, Thomas Olencki, Terri Malone, Kate Sandstrom, R Nadeau, Hema Parmar, Ronald M. Bukowski - 1998 cited by 231

  13. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

    Authors: Robert J. Motzer, Ronald M. Bukowski, Robert A. Figlin, Thomas E. Hutson, M. Dror Michaelson, Sindy T. Kim, Charles M. Baum, Michael W. Kattan - Cancer 2008 cited by 217

  14. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

    Authors: Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson, George Wilding, Gary R. Hudes, O. Bolte, Robert J. Motzer, Paul Bycott, Katherine Liau, James L. Freddo, Peter C. Trask, Sinil Kim, Brian I. Rini - The Lancet Oncology 2007 cited by 436

  15. Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma

    Authors: Robert A. Figlin, John A. Thompson, Ronald M. Bukowski, Nicholas J. Vogelzang, Andrew C. Novick, Paul H. Lange, Gary D. Steinberg, Arie S. Belldegrun - Journal of Clinical Oncology 1999 cited by 213

  16. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

    Authors: Brian I. Rini, David F. McDermott, Hans J. Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas E. Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins - Journal for ImmunoTherapy of Cancer 2016 cited by 122

  17. The Role of Inflammation in Kidney Cancer

    Authors: Antonio Roma de Vivar Chevez, James H. Finke, Ronald M. Bukowski - Advances in experimental medicine and biology 2014 cited by 108

  18. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Authors: Martin Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A. Bjarnason, Stéphane Oudard, Subramanian Hariharan, Se‐Hoon Lee, John B.A.G. Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul N. Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald M. Bukowski - The Lancet Oncology 2009 cited by 591

  19. Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

    Authors: Tarek Mekhail, Rony M. Abou-Jawde, Gabriel BouMerhi, Sareena Malhi, Laura S. Wood, Paul Elson, Ronald M. Bukowski - Journal of Clinical Oncology 2005 cited by 571

  20. Targeted Therapy for Metastatic Renal Cell Carcinoma

    Authors: Robert J. Motzer, Ronald M. Bukowski - Journal of Clinical Oncology 2006 cited by 457

  21. Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell Carcinoma

    Authors: Robert J. Motzer, Ashok Rakhit, John A. Thompson, John Nemunaitis, Barbara A. Murphy, Julie A. Ellerhorst, Lawrence H. Schwartz, William J. Berg, Ronald M. Bukowski - Journal of Interferon & Cytokine Research 2001 cited by 118

  22. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

    Authors: Bernard Escudier, Cezary Szczylik, Thomas E. Hutson, Tomasz Demkow, Michael Staehler, Frédéric Rolland, Sylvie Négrier, Nicole Laferriere, Urban Scheuring, David Cella, Sonalee Shah, Ronald M. Bukowski - Journal of Clinical Oncology 2009 cited by 491

  23. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

    Authors: Eric Van Cutsem, Paulo M. Hoff, Peter Harper, Ronald M. Bukowski, David Cunningham, P Dufour, Ullrich Graeven, J Lokich, Stefan Madajewicz, Jean A. Maroun, John L. Marshall, Edith P. Mitchell, G. Pérez-Manga, P. Rougier, Wolff Schmiegel, Juergen Schöelmerich, Alberto Sobrero, Richard L. Schilsky - British Journal of Cancer 2004 cited by 398

  24. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

    Authors: Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Münster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris - Clinical Cancer Research 2009 cited by 303